NCT04463017View on ClinicalTrials.gov

Ascending Dose Study of HU6 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

March 30, 2021

Study Completion Date

April 1, 2021

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

HU6

HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

Trial Locations (1)

55114

Prism Clinical Research, Saint Paul

All Listed Sponsors
lead

Rivus Pharmaceuticals, Inc.

INDUSTRY

NCT04463017 - Ascending Dose Study of HU6 in Healthy Volunteers | Biotech Hunter | Biotech Hunter